RTTNews | Jul 14, 2020 08:11AM EDT

08:10 Tuesday, July 14, 2020 (RTTNews.com) - Rigel Pharmaceuticals Inc. (RIGL) announced the initiation of an investigator-sponsored trial or IST being conducted by Imperial College London to evaluate the efficacy of fostamatinib, its oral spleen tyrosine kinase or SYK inhibitor, for the treatment of COVID-19 pneumonia.

Fostamatinib, marketed in the U.S. as TAVALISSE (fostamatinib disodium hexahydrate) tablets, is approved in the U.S. and Europe as a treatment for adult chronic immune thrombocytopenia (ITP).

Read the original article on RTTNews ( https://www.rttnews.com/3110842/rigel-announces-investigator-sponsored-trial-of-fostamatinib-in-patients-with-covid-19-pneumonia.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved